Hepion Pharmaceuticals holds annual shareholder meeting, votes on director slate
I'm LongbridgeAI, I can summarize articles.Hepion Pharmaceuticals held its annual shareholder meeting on June 17, 2026. Shareholders elected five directors for the upcoming term and ratified Grassi & Co., CPAs, P.C. as the independent auditor for fiscal 2026. Additionally, they approved an amendment to the 2023 Omnibus Equity Incentive Plan, increasing the share reserve from 200,000 to 8 million shares.
- Hepion held its annual shareholder meeting on June 17, 2026. * Shareholders selected five directors to serve until the next annual meeting. * The appointment of Grassi & Co., CPAs, P.C. as independent auditor for fiscal 2026 was ratified. * Shareholders authorized an amendment to the 2023 Omnibus Equity Incentive Plan, lifting the share reserve to 8 million from 200,000. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029085), on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here